61,763 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Castleark Management LLC

Castleark Management LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 2nd quarter, Holdings Channel reports. The firm purchased 61,763 shares of the biopharmaceutical company’s stock, valued at approximately $3,728,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its holdings in shares of Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after purchasing an additional 32,486 shares during the period. Jump Financial LLC acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $532,000. Sei Investments Co. acquired a new stake in Xenon Pharmaceuticals during the second quarter valued at approximately $711,000. The Manufacturers Life Insurance Company bought a new stake in Xenon Pharmaceuticals during the second quarter valued at $816,000. Finally, Alliancebernstein L.P. raised its stake in Xenon Pharmaceuticals by 14.2% during the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock worth $47,530,000 after acquiring an additional 189,141 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Activity

In related news, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the sale, the director owned 1,870 shares of the company’s stock, valued at approximately $119,792.20. This trade represents a 84.25% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on XENE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Needham & Company LLC reduced their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $77.13.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $60.42 on Wednesday. The firm has a market capitalization of $5.84 billion, a PE ratio of -12.75 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66. The company’s fifty day moving average price is $62.65 and its two-hundred day moving average price is $56.05.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same period in the prior year, the firm earned ($1.07) EPS. Analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.